DISC1, an oncogene, activates the GSK3β/β-catenin signaling to promote NSCLC growth, so it could be designed to be a novel anti-NSCLC therapeutic target (Wang et al., 2017), which means that HAL has the same mutation gene and differentiation process as NSCLC does. Here, HAL is linked to non-small cell lung carcinoma.